Chii chaitika
Quotient Sayenzi, sangano rekuUK-based retsvagiridzo yekondirakiti, uye Copenhagen-based biotech Acesion Pharma vakapinda mumubatanidzwa kuti vashandise tekinoroji yeQuotient's AI-enhanced formulation kune Acesion yekutanga-nhanho yeatrial fibrillation pombi. Kudyidzana uku kuchabatanidza inoshanda muchina-kudzidza uye Bayesian optimization algorithms muQuotient's Translational Pharmaceutics papuratifomu, ichibvumira sisitimu kuongorora data rekugadzira uye kupa zano remuromo-chigadzirwa sarudzo ine mukana wepamusoro wekusangana nezvinangwa zvebudiriro. Kudyidzana kunotevera mhedzisiro yenguva pfupi kubva kuongororo yekiriniki ichangoburwa umo Quotient's AI yakabudirira kusarudza yakagadziridzwa-kuburitswa maumbirwo akasangana neakafanotsanangurwa eparmacokinetic zvinangwa mukati menguva nhatu dzedosing.
Quotient Sciences and Acesion Pharma announced a formal collaboration aimed at leveraging Quotient’s AI‑enhanced formulation technology for Acesion’s early‑stage atrial fibrillation drug candidates. The partnership will embed active machine‑learning and Bayesian optimisation methods into Quotient’s Translational Pharmaceutics platform, which already combines formulation, development, and clinical activities.
The AI system will ingest formulation data and generate recommendations for oral drug‑product options that are more likely to meet predefined development objectives, such as target pharmacokinetic profiles. This is intended to enable development teams to make formulation decisions earlier in the , reducing the time and resources spent on trial‑and‑error experimentation.
Quotient cited interim results from a clinical study conducted earlier in the month, where its AI selected modified‑release formulation compositions and doses that achieved the study’s pharmacokinetic targets within three dosing periods. The success of that study underpins confidence in the technology’s ability to guide formulation decisions in a real‑world development context.
Both companies emphasized that the collaboration could shorten timelines to clinical testing and increase the probability of achieving the intended product profile for Acesion’s small‑molecule compounds. No pricing, licensing terms, or broader access details were disclosed.
Kwakabva mashoko: digitalhealthnews.com ↗
Nei zvichikosha
Kushandiswa kweAI-inotyairwa ekugadzira maturusi kunogona kupfupisa nguva inodiwa yekuziva vanogona kugadzirwa-chigadzirwa chemishonga, zvinogona kukurumidza kukurumidza nzira yekuongororwa kwekiriniki yeAcesion madiki-morekuru makomisheni. Nekudzikisira huwandu hwekuyedza kudzokorora, nzira yacho inogona kudzikisa mitengo yekuvandudza uye kuvandudza mukana wekuwana maprofile echigadzirwa, chinhu chakakosha pakurapa kwemoyo nhanho dzekutanga uko nguva dzakasimba. Kudyidzana uku kunoratidza kongiri, indasitiri-yakatarisana nekushandisa kwekushanda kwekudzidza uye Bayesian optimization, zvichiratidza kuvimba kuri kukura muAI kugadzirisa mishonga R&D kupfuura kuwanikwa kwekutanga.
Accelerating formulation decisions can have a direct impact on the overall drug‑development timeline, which is especially valuable for cardiovascular indications where market entry pressures are high.
By applying active learning and Bayesian optimisation, the partnership demonstrates a shift from heuristic, labor‑intensive formulation work toward data‑driven, predictive approaches, potentially setting a new standard for contract research organisations.
If successful, the AI‑enhanced workflow could reduce the number of failed formulation experiments, lowering R&D expenditures and freeing resources for other candidates.
The collaboration provides a concrete case study for the pharmaceutical industry on how AI can be integrated into existing translational platforms, offering a template for similar partnerships.
Interactive Mechanism: Iyo Inonyatsoshanda
Ongorora ari pasi tekinoroji kuseri kwekusimudzira uku uchipindirana.
crm_get_transaction(id='4092').Which component of an AI application is the machine-learning model itself?
Zvekutarisa zvinotevera
Future updates on the collaboration’s impact on Acesion’s atrial‑fibrillation , including any acceleration of clinical‑trial milestones. Additional data on the performance of the AI algorithms in real‑world formulation decisions, especially any comparative studies against traditional methods. Potential expansion of the AI‑enhanced platform to other therapeutic areas or to other contract research organisations.
Publication of any quantitative results comparing the AI‑guided formulation process to traditional methods, which would help validate the claimed efficiency gains.
Announcements of expanded use of the AI platform beyond atrial fibrillation, such as applications to other therapeutic areas or to other contract research partners.
Regulatory feedback or guidance on the use of AI‑generated formulation data in IND submissions, which could influence broader industry adoption.
Potential commercial licensing or service offerings from Quotient Sciences that make the AI‑enhanced technology available to a wider set of biotech and pharma clients.